ImmunoGen Stock Price Target and Analyst Ratings (NASDAQ:IMGN)

Analyst Price Target for IMGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$10.10

▲ +37.98% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for ImmunoGen in the last 3 months. The average price target is $10.10, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 37.98% upside from the last price of $7.32.

Buy

The current consensus among 7 polled investment analysts is to buy stock in ImmunoGen. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/29/2019

0 strong buy ratings
3 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/27/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/26/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/25/2020

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/23/2020

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/21/2021

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/16/2021	HC Wainwright	Boost Price Target	Buy	$11.00 ➝ $12.00	Low	i Rating by S. Ramakanth at HC Wainwright
12/7/2020	Piper Sandler	Boost Price Target	Neutral	$5.50 ➝ $6.50	Medium	i
11/9/2020	HC Wainwright	Reiterated Rating	Buy		Medium	i Rating by S. Ramakanth at HC Wainwright
11/6/2020	SVB Leerink	Boost Price Target	Market Perform	$5.00 ➝ $6.00	Low	i
10/26/2020	HC Wainwright	Reiterated Rating	Buy	$11.00	Low	i
10/20/2020	Canaccord Genuity	Reiterated Rating	Buy	$12.00	High	i
10/6/2020	SVB Leerink	Boost Price Target	Market Perform	$4.00 ➝ $5.00	Medium	i
10/2/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$14.00	High	i
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Low	i
9/18/2020	William Blair	Reiterated Rating	Buy		High	i
8/3/2020	Canaccord Genuity	Reiterated Rating	Buy		Low	i
6/1/2020	HC Wainwright	Reiterated Rating	Buy	$9.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
5/14/2020	Canaccord Genuity	Reiterated Rating	Buy	$12.00	High	i
5/4/2020	Canaccord Genuity	Reiterated Rating	Buy	$12.00	High	i
12/17/2019	HC Wainwright	Reiterated Rating	Buy	$5.00 ➝ $9.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
12/10/2019	HC Wainwright	Reiterated Rating	Buy	$5.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
12/10/2019	Cowen	Reiterated Rating	Buy		Low	i Rating by Boris Peaker at Cowen Inc
9/30/2019	Cowen	Reiterated Rating	Buy		High	i Rating by Boris Peaker at Cowen Inc
9/24/2019	SVB Leerink	Reiterated Rating	Hold		Medium	i Rating by Jonathan Chang at SVB Leerink LLC
8/13/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $5.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2019	HC Wainwright	Set Price Target	Buy	$4.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
6/27/2019	Cowen	Reiterated Rating	Buy		High	i
6/2/2019	Cowen	Reiterated Rating	Buy		Medium	i
5/16/2019	HC Wainwright	Lower Price Target	Buy	$7.00 ➝ $4.00	High	i Rating by D. Chattopadhyay at HC Wainwright
5/15/2019	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
5/6/2019	HC Wainwright	Upgrade	Neutral ➝ Buy	$7.00	High	i Rating by D. Chattopadhyay at HC Wainwright
5/6/2019	Cowen	Upgrade	Market Perform ➝ Outperform	$2.94	High	i
3/19/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		High	i
3/5/2019	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$2.68	Low	i
3/4/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		High	i Rating by J. Chang at SVB Leerink LLC
3/4/2019	HC Wainwright	Downgrade	Buy ➝ Neutral	$18.00 ➝ $3.50	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
3/1/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Medium	i
3/1/2019	Cowen	Reiterated Rating	Hold		High	i
3/1/2019	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High	i
3/1/2019	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$13.00 ➝ $2.50	High	i Rating by Joseph Catanzaro at Piper Jaffray Companies
1/3/2019	HC Wainwright	Reiterated Rating	Buy		Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
12/3/2018	HC Wainwright	Set Price Target	Buy	$18.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
12/2/2018	Piper Jaffray Companies	Set Price Target	Buy	$14.00	Medium	i Rating by Joseph Catanzaro at Piper Jaffray Companies
11/6/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
10/31/2018	HC Wainwright	Set Price Target	Buy	$18.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
10/22/2018	William Blair	Reiterated Rating	Outperform		High	i
10/22/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
10/8/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
9/17/2018	Guggenheim	Initiated Coverage	Buy		Low	i
9/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight		Low	i
7/30/2018	HC Wainwright	Reiterated Rating	Buy	$18.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
7/27/2018	Cowen	Reiterated Rating	Hold		High	i
6/13/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
6/5/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
5/17/2018	Cowen	Reiterated Rating	Hold		Medium	i
5/17/2018	HC Wainwright	Set Price Target	Buy	$18.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
5/7/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/27/2018	Canaccord Genuity	Reiterated Rating	Buy	$20.00	Low	i
4/25/2018	HC Wainwright	Set Price Target	Buy	$18.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
4/10/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$5.00	Low	i Rating by Mara Goldstein at Cantor Fitzgerald
3/26/2018	SVB Leerink	Reiterated Rating	Outperform		Medium	i Rating by J. Chang at SVB Leerink LLC
3/26/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
3/25/2018	Cantor Fitzgerald	Set Price Target	Hold	$5.00	High	i Rating by Mara Goldstein at Cantor Fitzgerald
3/21/2018	Royal Bank of Canada	Boost Price Target	Outperform	$16.00	Low	i
3/12/2018	HC Wainwright	Set Price Target	Buy	$18.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
2/12/2018	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
2/8/2018	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$12.00	Medium	i
1/31/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy		High	i Rating by D. Chattopadhyay at HC Wainwright
11/3/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$5.00	N/A	i Rating by Mara Goldstein at Cantor Fitzgerald
10/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$9.00	N/A	i
9/25/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$5.00	Medium	i Rating by Mara Goldstein at Cantor Fitzgerald
8/30/2017	Canaccord Genuity	Reiterated Rating	Buy	$8.00 ➝ $10.00	Medium	i Rating by John Newman at Canaccord Genuity
8/29/2017	Cowen	Reiterated Rating	Hold		High	i Rating by Boris Peaker at Cowen Inc
8/29/2017	SVB Leerink	Reiterated Rating	Outperform ➝ Buy		High	i Rating by M. Schmidt at SVB Leerink LLC
8/29/2017	Cantor Fitzgerald	Reiterated Rating	Hold		High	i Rating by Mara Goldstein at Cantor Fitzgerald
8/7/2017	Jefferies Financial Group	Reiterated Rating	Buy	$9.00	Medium	i
7/31/2017	Canaccord Genuity	Set Price Target	Buy	$8.00	High	i Rating by John Newman at Canaccord Genuity
7/28/2017	Cantor Fitzgerald	Set Price Target	Hold	$5.00	High	i Rating by Mara Goldstein at Cantor Fitzgerald
7/6/2017	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$5.00 ➝ $12.00	High	i Rating by Matthew Eckler at Royal Bank of Canada
6/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$6.00	High	i
6/26/2017	Royal Bank of Canada	Set Price Target	Hold	$5.00	N/A	i Rating by Matthew Eckler at Royal Bank of Canada
6/26/2017	William Blair	Reiterated Rating	Outperform		High	i Rating by A. Hsieh at William Blair
6/19/2017	SVB Leerink	Reiterated Rating	Outperform	$8.00 ➝ $11.00	High	i Rating by M. Schmidt at SVB Leerink LLC
6/4/2017	Cantor Fitzgerald	Set Price Target	Hold	$5.00	Medium	i Rating by Mara Goldstein at Cantor Fitzgerald
5/24/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$5.00	Low	i
5/19/2017	Canaccord Genuity	Set Price Target	Buy	$6.00	Low	i Rating by John Newman at Canaccord Genuity
5/18/2017	Jefferies Financial Group	Reiterated Rating	Buy	$6.00	High	i
5/8/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$5.00	High	i
5/6/2017	Canaccord Genuity	Set Price Target	Buy	$6.00	High	i Rating by John Newman at Canaccord Genuity
5/6/2017	Cowen	Reiterated Rating	Hold		High	i Rating by Boris Peaker at Cowen Inc
5/6/2017	Royal Bank of Canada	Set Price Target	Hold	$5.00	High	i Rating by Matthew Eckler at Royal Bank of Canada
4/19/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$3.53 ➝ $3.90	High	i Rating by M. Schmidt at SVB Leerink LLC
4/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$6.00	Low	i
3/13/2017	Cowen	Reiterated Rating	Hold		Medium	i
3/1/2017	Morgan Stanley	Lower Price Target	Underweight	$2.50 ➝ $1.30	N/A	i
2/18/2017	Canaccord Genuity	Set Price Target	Buy	$6.00	N/A	i Rating by John Newman at Canaccord Genuity
2/18/2017	Royal Bank of Canada	Set Price Target	Hold	$3.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
1/3/2017	Royal Bank of Canada	Reiterated Rating	Hold	$2.00	N/A	i
10/30/2016	Cantor Fitzgerald	Set Price Target	Hold	$5.00	N/A	i Rating by Mara Goldstein at Cantor Fitzgerald
10/28/2016	Canaccord Genuity	Set Price Target	Buy	$6.00	N/A	i Rating by John Newman at Canaccord Genuity
8/5/2016	Jefferies Financial Group	Reiterated Rating	Buy	$13.00 ➝ $6.00	N/A	i
8/5/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$9.00 ➝ $5.00	N/A	i Rating by Jessica Fye at JPMorgan Chase & Co.
6/8/2016	Cantor Fitzgerald	Reiterated Rating	Hold		N/A	i Rating by Mara Goldstein at Cantor Fitzgerald
6/6/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Boris Peaker at Cowen Inc
5/19/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$7.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
5/5/2016	Morgan Stanley	Reiterated Rating	Underweight	$9.00 ➝ $5.00	N/A	i
5/2/2016	SVB Leerink	Boost Price Target	Market Perform	$8.00 ➝ $11.00	N/A	i
4/30/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
4/29/2016	Cowen	Reiterated Rating	Hold	$8.50	N/A	i Rating by Boris Peaker at Cowen Inc
4/29/2016	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$18.00 ➝ $7.00	N/A	i

(Data available from 4/21/2016 forward)

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $7.32

$7.09

$7.37

50 Day Range

MA: $8.28

$7.18

$9.07

52 Week Range

Now: $7.32

$3.38

$10.88

Volume

1,114,561 shs

Average Volume

2,383,530 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoGen?

The following sell-side analysts have issued research reports on ImmunoGen in the last twelve months: Canaccord Genuity, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, SVB Leerink LLC, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IMGN.

What is the current price target for ImmunoGen?

5 Wall Street analysts have set twelve-month price targets for ImmunoGen in the last year. Their average twelve-month price target is $10.10, suggesting a possible upside of 39.7%. Guggenheim has the highest price target set, predicting IMGN will reach $14.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $6.00 for ImmunoGen in the next year.
View the latest price targets for IMGN.

What is the current consensus analyst rating for ImmunoGen?

ImmunoGen currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMGN will outperform the market and that investors should add to their positions of ImmunoGen.
View the latest ratings for IMGN.

What other companies compete with ImmunoGen?

Other companies that are similar to ImmunoGen include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Novavax, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, United Therapeutics and Neurocrine Biosciences.

How do I contact ImmunoGen's investor relations team?

ImmunoGen's physical mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company's listed phone number is 781-895-0600 and its investor relations email address is [email protected] The official website for ImmunoGen is www.immunogen.com.

NASDAQ:IMGN - ImmunoGen Stock Price Target and Predictions

Analyst Price Target for IMGN

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoGen?

What is the current price target for ImmunoGen?

What is the current consensus analyst rating for ImmunoGen?

What other companies compete with ImmunoGen?

How do I contact ImmunoGen's investor relations team?